AstraZenecaUS

We're transforming the future of healthcare by unlocking the power of what science can do. Intended for US HCPs. For info visit

[AstraZenecaUS @AstraZenecaUS]

We rang the opening bell in a historic moment today at the @NYSE. 

With #AZN trading on the #NYSE, we’re deepening our roots in the US and expanding our access to capital – fueling continued investment in the science behind a healthier America.

[AstraZenecaUS @AstraZenecaUS]

By deepening the collaboration between the UK and the US, we are accelerating scientific discovery and engaging with governments to deliver the next generation of medicines for patients worldwide.

[AstraZenecaUS @AstraZenecaUS]

Last week, we welcomed the US Ambassador to the UK, Warren Stephens, to The Discovery Center, our global headquarters and state-of-the-art R&D facility in Cambridge.

[AstraZenecaUS @AstraZenecaUS]

The visit was a fantastic opportunity to showcase the boundary-pushing science taking place at The DISC, our role in the Cambridge and UK life sciences ecosystem and our deep commitment to the United States.

[AstraZenecaUS @AstraZenecaUS]

Today, the FDA has approved a new treatment option for individuals living with hypereosinophilic syndrome (HES), a rare disease driven by elevated eosinophils in the blood, which can lead to progressive organ damage over time. Read more about the approval: https://t.co/yGWxyYURFK

[AstraZenecaUS @AstraZenecaUS]

The FDA just announced the approval of a new way to self-administer therapy for people living with systemic lupus erythematosus (SLE). Learn more: https://t.co/1Ra9EW94yG

[AstraZenecaUS @AstraZenecaUS]

Today, we begin trading on the @NYSE. This landmark moment makes it easier for investors to participate in our future and our ambitions to deliver innovative medicines to patients. https://t.co/1vZeU2APGM #AZN #NYSE

[AstraZenecaUS @AstraZenecaUS]

Rick R. Suarez is appointed Senior Vice President, US President and Head of US BioPharmaceuticals. He will lead the execution of our $50B US R&D and manufacturing investment and the Company’s US BioPharmaceuticals organization. Learn more: https://t.co/sBgAFbJ1jw

[AstraZenecaUS @AstraZenecaUS]

#News
With @GovWesMoore, we announced plans to invest $2 billion to expand our manufacturing footprint in Maryland, part of our $50 billion investment in the US. This will support 2,600 jobs & accelerate access to innovative therapies. https://t.co/9VTFPpfVXd

[AstraZenecaUS @AstraZenecaUS]

#News We're establishing a landmark partnership with the Commonwealth of Virginia, Eli Lilly, Merck and Virginia’s higher education institutions to create the largest workforce development hub in the US for advanced pharmaceutical manufacturing: https://t.co/3xh4qnVm7Y

[AstraZenecaUS @AstraZenecaUS]

Today, the FDA approved a new treatment option for chronic rhinosinusitis with nasal polyps (CRSwNP), offering patients an alternative way to help address their symptoms.

Read the full announcement: https://t.co/3BJyMlSFd3

[AstraZenecaUS @AstraZenecaUS]

#News Today we announced our plans to invest $4.5 billion in a new manufacturing facility in Virginia. This includes a proposed $500m increase to support enhanced manufacturing capability, driving life sciences innovation and economic growth: https://t.co/7INh1kgDZA

[AstraZenecaUS @AstraZenecaUS]

Today, with @DaiichiSankyoUS, we announced high-level results from the TROPION-Breast02 Phase III trial of our TROP2-directed antibody drug conjugate for 1st-line metastatic triple-negative #breastcancer. Learn more about these data: https://t.co/u52JcOViEN #AZUS

[AstraZenecaUS @AstraZenecaUS]

The FDA has approved a supplemental new drug application for an asthma rescue medication, which now includes clinically meaningful evidence in patients with mild asthma. Discover the implications this announcement has for asthma patients. https://t.co/6jLyDqHtdE

[AstraZenecaUS @AstraZenecaUS]

We’re proud to share promising phase III trial results highlighting our progress toward remission-driven lupus care.

Learn more about the high-level trial results: https://t.co/V6dRVMx2ja

[AstraZenecaUS @AstraZenecaUS]

Today, we’ve launched a new way to access our FDA-approved influenza vaccine, helping Americans stay protected during the flu season.

Millions get the flu each year, yet vaccination rates continue to decline. Learn more: https://t.co/5WuSUpZTkm

[AstraZenecaUS @AstraZenecaUS]

Today, in collaboration with @DaiichiSankyoUS we announced the @US_FDA approval of our treatment for adults with previously treated locally advanced or metastatic EGFR-mutated non-small cell #lungcancer #NSCLC.

Learn more: https://t.co/87rGEkeC6J #AZUS

[AstraZenecaUS @AstraZenecaUS]

Traditional approaches to asthma rescue may leave people with asthma at risk of exacerbations.

Learn more about our latest data, published in @NEJM: https://t.co/YpFxdHiir5 #ATS2025

[AstraZenecaUS @AstraZenecaUS]

Today, with @DaiichiSankyoUS, we announced high-level results from our DESTINY-Breast11 Phase III trial for HER2-positive early #breastcancer in the neoadjuvant setting. Learn more about the data and its potential impact for patients: https://t.co/cOgv0OhppE #AZUS

[Aruna K. Miller @arunamiller]

Yesterday, we joined @AstraZenecaUS to celebrate a $300 million investment in their new cell therapy facility in Montgomery County —bringing 150 high-skilled jobs & new hope in the fight against cancer.

It was great to be joined by the entire District 15 team Senator @BrianJFeldman , Delegates @fraserfor15 , @LilyQiMaryland & Linda Foley, along with Senator Malcolm Augustine, @MontCoExec Marc Elrich & Rockville Mayor Monique Ashton—as well as Secretaries Harry Coker and Sanjay Rai from the Moore-Miller administration.